N/A N=31 Correlation of Anal Acoustic Reflectometry Parameters With Degree of Rectal Intussusception and Prolapse
Pelvic Floor Disorders
Primary: Opening Pressure — 56.35; 39.01; 23.42 cmH20
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=63 Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy
Hypertensive Anal Canal
Primary: Effect of Closed Lateral Sphincterotomy and Chemical Sphincterotomy on Hypertensive Anal Canal
N/A N=40 Evaluation of the Rectal Reflex Using Anal Acoustic Reflectometry
Pelvic Floor Dysfunction
Primary: Opening Pressure — 34.44; 15.41 cmH2O
N/A N=52 Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM
Obstructed Defecation Syndrome · Rectocele · Intussusception
Primary: Quality of Life — 3.2; 3.7; 2.8; 3.3 units on a scale — p=0.1340
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Phase 4 N=109 Prospective Randomized Controlled Trial of an Enhanced Recovery Protocol for Anorectal Surgery
Anorectal Disorder
Primary: Total Narcotic Use Postoperatively in Oral Morphine Equivalents — 8; 79 Oral morphine miligram equivalents
N/A N=124 Effects of an Anal Insert Device in Fecal Incontinence
Fecal Incontinence
Primary: Primary Effectiveness Endpoint — 75.9 percentage of treatment responders
N/A N=121 The Role of Biofeedback in Improving Continence After Anterior Resection
Rectal Neoplasms · Fecal Incontinence · Aged
Primary: Cleveland Clinic Incontinence (CCI) Score — 4.2; 3.7; 1.2; -0.7 score on a scale — p=0.54
N/A N=20 The Use of an "Anal-Tape" in Patients With Fecal Incontinence
Fecal Incontinence
Primary: Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs) — 2.8; 3.3; 1.9; 2.5 score on a scale
Phase 4 N=75 Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
Obstructive Defecation Syndrome · Chronic Constipation · Rectocele
Primary: Percentage of Change (Reduction) in Total ODS Symptom Composite Score From Baseline to One Year Post Procedure — 60.8 percentage of change
Phase 3 N=300 Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)
Fecal Incontinence
Primary: Change From Baseline St. Mark's (Vaizey) Score — -5.5; -4.4; -4.5; -3.4 units on a scale — p=0.092
N/A N=80 Video-assisted Anal Fistula Treatment Versus Seton in the Management of High Peri Anal Fistula
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
Phase 2 N=74 Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions
Constipation
Primary: Weekly Rate of Spontaneous Bowel Movements at 4 Weeks — 1.6; 1.3; 1.6; 1.3 spontaneous bowel movements per week — p=0.78
N/A N=120 Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence
Fecal Incontinence
Primary: Proportion of Subjects With at Least 50% Reduction in Number of Incontinent Episodes Per Week — 0.73 proportion of subjects — p=<0.0001
N/A N=46 Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
N/A N=1,718 Prevalence and Treatment of Anal Incontinence (AI) in Primiparous Women
Fecal Incontinence
Primary: Change in Anal Incontinence as Measured on the St. Mark's Score — 4.3; 4.5; 3.6; 4.1 units on a scale
N/A N=100 A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas
Anorectal Fistulas
Primary: Fistula Healing in Patients at 6 Months Following Surgery — 56.7; 43.3 percentage of participants
N/A N=10 A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia
Anal Intraepithelial Neoplasia (AIN) · High-grade Squamous Intraepithelial Lesions (HSIL)
Primary: Related Adverse Events — 1; 1 number of participants
N/A N=32 Randomized Clinical Trial on Transanal Irrigation
Low Anterior Resection Syndrome
Primary: LARS Score — 21.3; 32.2 score on a scale
N/A N=300 War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)
Hemorrhoids · Hemorrhoidal Disease
Primary: Hemorrhoid Regression Rate — 117; 33 Participants — p=<0.001
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
N/A N=36 Evaluation of the Fast Fill Technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter
Faecal Incontinence
Primary: Opening Pressure — 35.13; 37.5 cmH2O
Phase 3 N=465 Diltiazem Hydrochloride Cream for Anal Fissure
Chronic Anal Fissure
Primary: Change From Baseline in Average of Worst Anal Pain Associated With or Following Defaecation for Week 4 (for the 7 Treatment Days Immediately Preceding the Week 4 Visit)…
N/A N=104 Spontaneous Void Requirements for Patients Undergoing Ambulatory Anorectal Surgery
Complications, Postoperative
Primary: PACU Time — 129.1; 210.0 Minutes
N/A N=12 Proof of Concept: "Bottom's Up" Seat to Treat Constipation
Constipation Aggravated · Pelvic Floor; Incompetency
Primary: Adverse Events — 0 Participants
N/A N=20 An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders
Encopresis · Autistic Disorder
Primary: Percent Continent — 0; 0; 6; 0 percentage of participants
N/A N=50 Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of PROCTOeze® PLUS
Haemorrhoidal Disease
Primary: Assessment of Performance by the Improvement in the Quality of Life Measured Through the Score on The Short Health Scale for Haemorrhoidal Disease (SHSHD) — 14.04; 7.80…
Phase 2 N=53 Autologous Cell Therapy for Treatment of Fecal Incontinence
Fecal Incontinence
Primary: Number of Treatment-Related Adverse Events — 0; 1; 5; 28 events
N/A N=18 Developing Rectal USPE Measures
Microbicide Delivery System Perceptibility and Acceptability
Primary: User Sensory Perception & Experience (USPE; Perceptibility) Scale Item Means — 3.67; 3.29; 3.86; 3.42 units on a scale